175 related articles for article (PubMed ID: 1369122)
21. Antisense strategies.
Crooke ST
Curr Mol Med; 2004 Aug; 4(5):465-87. PubMed ID: 15267220
[TBL] [Abstract][Full Text] [Related]
22. Antisense oligonucleotides: towards clinical trials.
Agrawal S
Trends Biotechnol; 1996 Oct; 14(10):376-87. PubMed ID: 8987636
[TBL] [Abstract][Full Text] [Related]
23. [Oncogenes and pharmacological approaches to cancer therapy].
Tocque B
Pathol Biol (Paris); 1992 Nov; 39(9):869-70. PubMed ID: 1538914
[No Abstract] [Full Text] [Related]
24. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2.
Zanardi TA; Han SC; Jeong EJ; Rime S; Yu RZ; Chakravarty K; Henry SP
J Pharmacol Exp Ther; 2012 Nov; 343(2):489-96. PubMed ID: 22915769
[TBL] [Abstract][Full Text] [Related]
25. Safety of antisense oligonucleotide and siRNA-based therapeutics.
Chi X; Gatti P; Papoian T
Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
[TBL] [Abstract][Full Text] [Related]
26. Progress in antisense therapeutics.
Crooke ST
Hematol Pathol; 1995; 9(2):59-72. PubMed ID: 7559256
[TBL] [Abstract][Full Text] [Related]
27. Antisense therapeutics.
Crooke ST
Biotechnol Genet Eng Rev; 1998; 15():121-57. PubMed ID: 9573607
[No Abstract] [Full Text] [Related]
28. ISIS-14803 (Isis Pharmaceuticals).
Witherell GW
Curr Opin Investig Drugs; 2001 Nov; 2(11):1523-9. PubMed ID: 11763152
[TBL] [Abstract][Full Text] [Related]
29. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany.
Uhlmann E
Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
[TBL] [Abstract][Full Text] [Related]
31. Developing oligonucleotide therapeutics for human leukemia.
Gewirtz AM
Anticancer Drug Des; 1997 Jul; 12(5):341-58. PubMed ID: 9236851
[No Abstract] [Full Text] [Related]
32. Design and applications of modified oligonucleotides.
Gallo M; Montserrat JM; Iribarren AM
Braz J Med Biol Res; 2003 Feb; 36(2):143-51. PubMed ID: 12563516
[TBL] [Abstract][Full Text] [Related]
33. Oligonucleotide treatment of ras-induced tumors in nude mice.
Wickstrom E
Mol Biotechnol; 2001 May; 18(1):35-55. PubMed ID: 11439698
[TBL] [Abstract][Full Text] [Related]
34. Oligonucleotide-mediated modulation of mammalian gene expression.
Scanlon KJ; Ohta Y; Ishida H; Kijima H; Ohkawa T; Kaminski A; Tsai J; Horng G; Kashani-Sabet M
FASEB J; 1995 Oct; 9(13):1288-96. PubMed ID: 7557018
[TBL] [Abstract][Full Text] [Related]
35. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides.
Hélène C
Eur J Cancer; 1991; 27(11):1466-71. PubMed ID: 1835863
[TBL] [Abstract][Full Text] [Related]
36. A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.
Cunningham CC; Holmlund JT; Geary RS; Kwoh TJ; Dorr A; Johnston JF; Monia B; Nemunaitis J
Cancer; 2001 Sep; 92(5):1265-71. PubMed ID: 11571742
[TBL] [Abstract][Full Text] [Related]
37. Antisense of oligonucleotides and the inhibition of oncogene expression.
Prins J; de Vries EG; Mulder NH
Clin Oncol (R Coll Radiol); 1993; 5(4):245-52. PubMed ID: 8398922
[TBL] [Abstract][Full Text] [Related]
38. Antisense oligonucleotide derivatives as gene-targeted drugs.
Knorre DG; Vlassov VV
Biomed Sci; 1990 Apr; 1(4):334-43. PubMed ID: 1723003
[TBL] [Abstract][Full Text] [Related]
39. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
40. Antisense oligonucleotides: promise and reality.
Lebedeva I; Stein CA
Annu Rev Pharmacol Toxicol; 2001; 41():403-19. PubMed ID: 11264463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
